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Abstract Proinflammatory cytokines, a combination of IL-1L,
TNF-K, and IFN-Q, caused mRNA expression of GTP cyclohy-
drolase I (GTP-CH), the rate-limiting enzyme in tetrahydro-
biopterin (BH4) biosynthesis, and of inducible nitric oxide
synthase (iNOS) in a well-characterized osteoblastic clone
MC3T3-E1 cell line. We found the expression of the GTP-CH
gene in osteoblasts for the first time. The expression of GTP-CH
and iNOS mRNAs was found to be maximal at 3 and 9 h,
respectively. The expression of both genes elicited increases in
BH4 and NO levels. Pharmacological studies using 2,4-diamino-
6-hydroxypyrimidine, an inhibitor of GTP-CH activity, showed
that BH4 is involved in the activity of iNOS, but not in the
induction of iNOS mRNA. The results using an inhibitor of
nuclear factor (NF)-UB and activating protein-1 (AP-1) activa-
tion suggested that coinduction of the two genes in response to
cytokines occurred via activation of NF-UB and AP-1. In
MC3T3-E1 cells BH4 and sepiapterin, producing BH4, could
protect against apoptosis, i.e. the degradation of nuclear DNA in
the cells, induced by NO derived from S-nitroso-N-acetyl-D,L-
penicillamine. These results suggest that the induction of BH4
together with NO by proinflammatory cytokines could protect
against NO-induced apoptosis in MC3T3-E1 cells.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
GTP cyclohydrolase I (GTP-CH, EC 3.5.4.16) is the ¢rst
and rate-limiting enzyme in the biosynthesis of tetrahydro-
biopterin (BH4). The biosynthesis of BH4 is completed by
the subsequent action of 6-pyruvoyl-tetrahydropterin synthase
and sepiapterin reductase. The ¢nal product, BH4, serves as a
cofactor for the three isoforms of nitric oxide synthase (NOS)
[1] and is required for the dimerization and stability of the
inducible nitric oxide synthase (iNOS) protein [2^4], and for
the protection of NOS activity from inhibition by its product,
NO [5].
Since NO has been reported to be released from osteoblast-
like cells [6] and to inhibit osteoclastic activity in vitro [6,7],
the role of NO as a regulatory molecule in bone has been
scrutinized. Recent studies on osteoblast-like cells demon-
strated the expression of mRNA, enzyme protein, and enzyme
activity of iNOS, which are all induced by proin£ammatory
cytokines and/or endotoxin among various species, and sug-
gested that osteoblast-derived NO may have an important
role in the regulation of cell proliferation and function [8^
11]. It is well known that in many other cells, including ¢bro-
blasts, brain endothelial cells, vascular smooth muscle cells,
and the macrophage cell line RAW264.7, the induction of NO
synthesis by proin£ammatory cytokines and/or endotoxin is
parallel to an enhanced formation of BH4 and an up-regula-
tion of GTP-CH [12^20], and conversely, is suppressed by an
inhibitor of GTP-CH [13,15^19]. Thus, BH4 may serve as a
cofactor to support the induction of iNOS and the production
of NO. Recent observations on vascular smooth muscle that
activation of nuclear factor (NF)-UB, which may mediate the
induction of NOS [21,22], underlies the induction of GTP-CH
gene expression by an immunostimulant [23], suggest that NF-
UB may also operate in osteoblasts in controlling GTP-CH
gene activity and the expression of the BH4 phenotype.
The aim of the present study was to elucidate the regulation
of the GTP-CH and iNOS genes in osteoblasts. We compared
the expression of the GTP-CH gene with that of the iNOS
gene in response to cytokines, examined the transcriptional
mechanism for these inductions, and investigated the physio-
logical signi¢cance of coinduction of GTP-CH and iNOS
mRNAs. We analyzed the steady-state as well as inducible
expression of GTP-CH mRNA in mouse osteoblast-like cells
(MC3T3-E1), and examined the e¡ects of NO and BH4 on
nuclear DNA fragmentation during these inductions.
2. Materials and methods
2.1. Materials
MC3T3-E1 cells, established from newborn mouse calvaria by Ko-
dama et al. [24], were kindly supplied by Dr. Amagai (Oou University,
Koriyama, Japan). Alpha-modi¢ed minimum essential medium (K-
MEM) was obtained from Gibco-BRL Laboratories (Grand Island,
NY, USA); fetal calf serum (FCS) was from Cell Culture Laborato-
ries (Cleveland, OH, USA). Tissue culture dishes were obtained from
Falcon Plastics (Los Angeles, CA, USA). Human recombinant IL-1L,
TNF-K, and IFN-Q were from Genzyme (Cambridge, MA, USA). The
hemisulfate salt of 2,4-diamino-6-hydroxypyrimidine (DAHP), pyrro-
lidine dithiocarbamate (PDTC), curcumin and BH4 were obtained
from Sigma Chemical Co. (St. Louis, MO, USA). S-Nitroso-N-ace-
tyl-D,L-penicillamine (SNAP) and L-sepiapterin were obtained from
Wako Pure Chemicals (Osaka, Japan). All other chemicals used
were of reagent grade.
2.2. Cell culture of MC3T3-E1 cells
Cloned MC3T3-E1 cells were cultured in plastic dishes in K-MEM
supplemented with 10% FCS, 100 IU/ml penicillin, and 100 Wg/ml
streptomycin at 37‡C in air with 5% CO2 and were then subcultured
until they were almost con£uent. For the experiments to examine gene
expression, cells were plated at 106 cells per 10 cm diameter dish and
con£uent cell cultures were used in all experiments.
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2.3. Analysis of mRNA levels by reverse transcription-polymerase chain
reaction (RT-PCR)
RNA was extracted from osteoblast-like cells in a 10-cm dish by the
guanidinium isothiocyanate method [25]. RT-PCR was performed us-
ing standard methods, as previous reported [26]. Brie£y, at ¢rst cDNA
was synthesized using random primers and Moloney murine leukemia
virus reverse transcriptase (Gibco-BRL), followed by PCR ampli¢ca-
tion using synthetic gene primers speci¢c for mouse iNOS, mouse
GTP-CH, and mouse glyceraldehyde 3-phosphate dehydrogenase
(G3PDH) produced from the reported cDNA sequences, respectively
[27^29]. The oligonucleotide primers were synthesized on a DNA
synthesizer (Expedite model 8909; PerSeptive biosystem, Cambridge,
MA, USA), and puri¢ed on a polypropylene ¢lter (Oligo Prep kit;
Pharmacia Biotech, Uppsala, Sweden). Primers used were as follows:
iNOS forward 25-mer, 5P-CCCTTCCGAAGTTTCTGGCAGCAGC-
3P ; iNOS reverse 25-mer, 5P-GGCTGTCAGAGCCTCGTGGCTTT-
GG-3P ; GTP-CH forward 21-mer, 5P-TACTCGTCCATTCTGCT-
CTCG-3P ; GTP-CH reverse 21-mer, 5P-GTCTTGCTGTTCATTTT-
CTGC-3P ; G3PDH forward 20-mer, 5P-ACCACAGTCCATGCC-
ATCAC-3P ; G3PDH reverse 20-mer, 5P-TCCACCACCCTGTTG-
CTGTA-3P. PCR ampli¢cation was performed with a GeneAmp
PCR System (Perkin Elmer/Cetus, Norwalk, CT, USA) according to
the following schedule: denaturation at 95‡C for 30 s, annealing at
55‡C for 30 s, and elongation at 72‡C for 1 min for appropriate
cycles. PCR products were electrophoresed on a 2% Nusieve GTG
agarose gel (FMC Bioproducts, Rockland, ME, USA) and stained
with ethidium bromide. All PCR reactions resulted in the ampli¢ca-
tion of a single product of the predicted size for iNOS (497 bp), GTP-
CH (452 bp), and G3PDH (452 bp), which products were detected
with a FluorImager 575 (Molecular Dynamics, Sunnyvale, CA, USA).
2.4. Determination of nitrite and biopterin
Quantitative analysis of total biopterin (tetrahydrobiopterin plus
oxidized species) was done essentially as described by Fukushima
and Nixon [30]. Total NO (nitrite plus nitrate) was determined with
a commercially available kit based on the Griess reaction (Cayman
Chemical, Ann Arbor, MI, USA).
2.5. Analysis of DNA fragmentation and cytotoxicity
Cellular DNA fragmentation assay was performed by the detection
of BrdU-labeled DNA fragments in the cytoplasm of cell lysates by
solid phase-immobilized anti-DNA MoAb and anti-BrdU MoAb la-
beled with peroxidase (cellular DNA fragmentation ELISA, Boehr-
inger Mannheim, Mannheim, Germany). In short, MC3T3-E1 cells
grown in a culture dish (2U105 cells/ml) were labeled with BrdU
for 15 h (batch labeling). After labeling, the cell concentration was
adjusted to 1U105 cells/ml, and 100 Wl/well were transferred to a
microtiter plate (96 wells, £at bottom), and then incubated in the
presence of di¡erent concentrations of SNAP (0.125^1 mM) mixed
with sepiapterin (0.5 mM) for 8 h at 37‡C in a humidi¢ed atmosphere
(5% CO2). The amount of BrdU-labeled DNA released into the
cytoplasm of apoptotic cells was quanti¢ed by ELISA [31,32].
The cytotoxicity was determined by lactate dehydrogenase (LDH)
release measured by a commercially available assay kit (Boehringer
Mannheim, Mannheim, Germany). The values (mean þ S.E.M.) for
LDH release are presented as the percentage of total LDH (extra-
cellular plus intracellular LDH). Cellular LDH were determined by
permeabilizing cells with 1% Triton X-100.
3. Results and discussion
This is the ¢rst report to demonstrate that osteoblasts are
able to express GTP-CH, a rate-limiting enzyme for BH4 syn-
thesis following stimulation by cytokines. We con¢rmed that
iNOS mRNA was also expressed in response to cytokines, as
observed in various osteoblast-like cells [8^11]. As shown in
Fig. 1, RT-PCR analysis showed that GTP-CH and iNOS
mRNAs were not detected at the steady-state but that their
level was rapidly increased by exposure of the cells to a com-
bination of IL-1L (100 U/ml), TNF-K (1 ng/ml), and IFN-Q
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Fig. 1. Time course of the e¡ect of proin£ammatory cytokines on coinduction of GTP-CH and iNOS mRNAs in MC3T3-E1 cells. A: RT-
PCR analysis for mRNA obtained from cells treated with cytokines (IL-1L 100 U/ml, TNF-K 1 ng/ml, and IFN-Q 200 U/ml) for 0, 1, 3, 6, 9,
12, and 24 h. DNA size markers (PX174/HaeIII digest) are shown in the left lanes (S). Numbers in parentheses on the right indicate cycles of
PCR ampli¢cation. Arrowheads indicate the predicted size of PCR products. B: Relative expression of these inductions. The mRNA level of
GTP-CH and iNOS was calculated by dividing the intensity of the GTP-CH and iNOS bands by the intensity of the G3PDH band as deter-
mined by a £uoresent image analyzer. Pooled data from four independent experiments are expressed as means þ S.E.M.
Table 1
E¡ect of DAHP on biopterin and NO productions in MC3T3-E1
cells treated with cytokines
Biopterin (nmol/well) NO (pmol/well)
Control n.d. 2.80 þ 0.35
Cytokines 0.50 þ 0.06 4.70 þ 0.24
+DAHP (1.25 mM) 0.10 þ 0.01 3.60 þ 0.35
+DAHP (2.5 mM) n.d. 2.50 þ 0.35
Biopterin content in cell lysate and NO accumulation in culture me-
dium were detemined at 24 and 48 h, respectively, after exposure to
cytokines (IL-1L 100 U/ml, TNF-K 1 ng/ml, and IFN-Q 200 U/ml).
DAHP was added 3 h before treatment with cytokines. Each value is
the mean þ S.E.M. (n = 6). n.d.: not detectable under the present ex-
perimental condition.
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(200 U/ml). As shown in Fig. 1B, the expression of GTP-CH
and iNOS mRNAs was found to be maximal at 3 and 9 h,
respectively, and followed by a decline after 24 h of exposure
to the cytokines. Thus, the expression of GTP-CH occurred
slightly but substantially prior to the expression of iNOS in
response to the cytokines. Individual cytokines had a distinct
e¡ect on GTP-CH and iNOS gene expressions. IL-1L (100 U/
ml) induced the expression of both genes; TNF-K (1 ng/ml)
induced the expression of the GTP-CH gene but not that of
the iNOS gene; and IFN-Q (200 U/ml) did not induce the
expression of either gene. The gene expression by individual
cytokines, IL-1L and TNF-K, was lower than that by cytokine
mixtures, IL-1L plus TNF-K plus IFN-Q (data not shown).
This may indicate that IFN-Q synergistically augments the
e¡ects of IL-1L and/or TNF-K and increases NO and BH4
production in osteoblastic cells.
High-output generation of NO by iNOS and synthesis of
BH4 have been demonstrated to be coinduced in mouse ¢bro-
blasts, murine brain endothelial cells, and rat vascular smooth
muscle cells [12^20]. Conversely, DAHP, which is an inhibitor
of GTP-CH activity, reduces both the intracellular BH4 con-
tent and the accumulation of NO in the respective cultures
[13,15,16]. Furthermore, it has been reported that BH4 is nec-
essary not only for the activity but also for the expression of
iNOS in human mesangial cells and that the inhibition of de
novo BH4 synthesis with DAHP signi¢cantly attenuated
iNOS activity as well as mRNA and protein expression in
response to IL-1L/TNF-K [33]. These results may indicate
that BH4 availability plays an important role in the regulation
of iNOS expression. In the present study, we also observed
signi¢cant increases in total biopterin and NO by cytokines as
well as the signi¢cant inhibition by DAHP of these increases
in osteoblasts, MC3T3-E1 cells (Table 1). As the inhibitory
e¡ect of DAHP was at least partially reversed by a precursor
of BH4, sepiapterin, we concluded that DAHP downregulates
the production of NO via reduced formation of BH4. To
examine whether or not biosynthesis of BH4 was necessary
to induce iNOS mRNA after exposure to cytokines, we
studied the in£uence of DAHP on expression of iNOS
mRNA. As shown in Fig. 2, the induction of iNOS mRNA
by cytokines was not a¡ected in mouse osteoblastic cells
treated with DAHP (1.25^10 mM).
Recent analyses of promoter sequences showed the presence
of cytokine-responsive elements for the binding of transcrip-
tional factors such as activating protein-1 (AP-1) and NF-UB
in murine iNOS gene [34], and NF-UB activation is known to
be required for cytokine-induced iNOS mRNA expression
[21,22]. PDTC inhibits NF-UB activation by suppressing the
release of the inhibitory subunit IUB from the latent form of
NF-UB [35]; and curcumin inhibits AP-1 binding to its con-
sensus sequence [36]. We tested the e¡ect of PDTC and cur-
cumin on the expression of iNOS and GTP-CH mRNAs in
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Fig. 2. E¡ect of DAHP on iNOS and GTP-CH mRNA inductions
in MC3T3-E1 cells treated with cytokines. RT-PCR analysis for
mRNA obtained from cells treated with DAHP in the presence or
absence of cytokines. DAHP (1.25^10 mM) was added 3 h before
treatment with cytokines. DNA size markers (PX174/HaeIII digest)
are shown in the left lanes (S). Numbers in parentheses indicate
cycles of PCR ampli¢cation. Arrowheads indicate the predicted size
of PCR products.
Fig. 3. E¡ects of PDTC and curcumin on induction of GTP-CH and iNOS mRNAs in MC3T3-E1 cells treated with cytokines. A: E¡ects of
PDTC (25^100 WM) on induction of GTP-CH (b) and iNOS (a) mRNAs by cytokines. Relative expression of these inductions. The mRNA
level of GTP-CH and iNOS was calculated by dividing the intensity of the GTP-CH and iNOS bands by the intensity of the G3PDH band as
determined by a £uoresent image analyzer. Pooled data from three independent experiments are expressed as means þ S.E.M. B: E¡ects of cur-
cumin (7.5^30 WM) on induction of GTP-CH (b) and iNOS (a) mRNAs by cytokines. Pooled data from three independent experiments are ex-
pressed as means þ S.E.M. C: Agarose gel electrophoresis of GTP-CH and iNOS mRNAs in cells treated with PDTC and/or curcumin. PDTC
(50 WM) and/or curcumin (30 WM) were added 3 h before treatment with cytokines. DNA size markers (PX174/HaeIII digest) are shown in the
left lanes (S). Numbers in parentheses indicate cycles of PCR ampli¢cation. Arrowheads indicate the predicted size of PCR products.
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osteoblastic cells (Fig. 3). The cytokine-induced expression of
iNOS mRNA was abolished by either PDTC (50 WM) or
curcumin (30 WM), suggesting that both NF-UB and AP-1
activation may be required for the cytokine-induced expres-
sion of the iNOS gene. On the other hand, the expression of
GTP-CH mRNA induced by cytokines was not abolished by
either PDTC or curcumin, but was abolished by PDTC plus
curcumin. This ¢nding suggests that dual operation of NF-UB
stimulation and AP-1 activation is essential for the induction
of cytokine-induced expression of the GTP-CH gene. Thus,
these pharmacological experiments indicated that the activa-
tion of NF-UB and AP-1 may be involved in the expression of
both iNOS and GTP-CH mRNAs in osteoblastic cells. The
inhibitory e¡ect of PDTC and/or curcumin on gene expression
induced by combined cytokines was also observed on gene
expression by individual cytokines (data not shown).
It is an interesting problem to elucidate the physiological
meaning of the coinduction of iNOS and GTP-CH genes in
response to cytokines in mouse osteoblastic cells. There are
some data suggesting physiological signi¢cance for the coin-
duction, which increases the NO as well as BH4 content in the
cells. In osteoblastic cells, cytokine-induced increases in NO
production have been reported to be associated with a marked
inhibition of proliferation [8,9]. This inhibition was reversed
by abrogation of NO synthesis with the competitive inhibitor
of NO synthase under these conditions, suggesting that NO
may be responsible for the inhibition of osteoblastic prolifer-
ation induced by these cytokines (the combination of IL-1L,
TNF-K and IFN-Q). Recently, it was demonstrated that ele-
vating intracellular BH4 levels signi¢cantly enhanced the pro-
liferation of rat PC12 cells, rat C6 glioma, and human ¢bro-
blasts above basal proliferation rates [37]. These ¢ndings
suggest that the action of NO on cell proliferation is the
opposite of that of BH4. To determine the physiological in-
teraction between BH4 and NO in osteoblastic cells, we exam-
ined the e¡ects of these products on nuclear DNA degrada-
tion, which is regarded as a hallmark of apoptotic cell death
[38], in light of the recent observation of NO-induced apop-
tosis in osteoblastic cells [39]. As shown in Fig. 4, sepiapterin
(0.5 mM), known to produce BH4 through the pterin salvage
pathway within cells, as well as BH4 (1 mM) signi¢cantly
inhibited DNA fragmentation induced by SNAP (0.125
mM), an NO generator. In the cells showing DNA fragmen-
tation by treatment of SNAP (0.125 mM) for 8 h, no signi¢-
cant increase in LDH release was observed (basal LDH re-
lease 18.0 þ 2.5%, SNAP-induced LDH release 16.5 þ 2.5%),
suggesting that necrotic cell death, if present, represents a
minor pathway of SNAP-induced cytotoxicity in MC3T3-E1
cells. This result indicates that BH4 may protect against the
degradation of nuclear DNA induced by NO, suggesting
physiological antagonism for cell viability by these products.
In conclusion, the present ¢ndings indicate that coinduction
of iNOS and GTP-CH mRNAs in response to cytokines,
which elicited increases in NO and BH4 levels, occurs prob-
ably via NF-UB and AP-1 activation in mouse osteoblastic
cells and that BH4 is involved in the activity of iNOS, but
not in the induction of iNOS mRNA. As a physiological sig-
ni¢cance of gene expression of GTP-CH with iNOS induced
by proin£ammatory cytokines, we propose that the induction
of BH4 synthesis due to GTP-CH gene expression may have
protective activity against NO-induced apoptosis.
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